Immuno-Oncology

The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

FDA Approved Products or Drugs-Olivier Le Moal-stock.adobe.com.jpeg
FDA Approves Pembrolizumab With Chemotherapy in Advanced Endometrial Carcinoma

June 17th 2024

The FDA approved pembrolizumab (Keytruda) plus carboplatin and paclitaxel, followed by single-agent pembrolizumab, in adult patients with primary advanced or recurrent endometrial carcinoma.

Blue FDA Approved stamp | Image credit: Olivier Le Moal - stock.adobe.com
Durvalumab Plus Chemotherapy Receives Approval for dMMR Primary Advanced or Recurrent Endometrial Cancer

June 16th 2024

Blinatumomab logo | Image credit: Amgen
Blinatumomab Approved in Consolidation Phase for CD-19+ Ph-Negative Precursor B-ALL, “Redefines Standard of Care”

June 14th 2024

Esophageal cancer illustration | Image credit: Dr_Microbe - stockadobe.com
Tislelizumab Plus Chemo Meaningfully Improves OS, PFS in Advanced Esophageal Cancer

June 14th 2024

CAR T-cell therapy | Image credit: Getty Images Science Library
Whither CAR T? Will the FDA Being Under the Hood and the Availability of Bispecifics Make These Therapies Less Attractive?

June 12th 2024

More News

Esophageal cancer
February 7th 2023

Zanidatamab, With Biparatopic Binding to HER2, Shows 84% OS in Phase 2 Study of Gastroesophageal Adenocarcinoma

Mary Caffrey
The investigational therapy promises a new way to target HER2 while still using chemotherapy combinations.
Dr Jeremy Abramson Discusses CAR T-Cell Therapy Timing in DLBCL
February 4th 2023

Dr Jeremy Abramson Discusses CAR T-Cell Therapy Timing in DLBCL

Hayden E. Klein Rose McNulty
Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, shared his take on the potential benefits of chimeric antigen receptor (CAR) T-cell therapy in earlier lines of treatment.
Study Finds Link Between Tumor Microbiome and Immunotherapy Outcomes in Soft Tissue Sarcoma
February 3rd 2023

Study Finds Link Between Tumor Microbiome and Immunotherapy Outcomes in Soft Tissue Sarcoma

Rose McNulty
The study suggests there is measurable amount of microbiome within the soft tissue sarcoma tumor environment, which was previously thought to be sterile.
'Persistent' Subset of Tumor Mutations May Predict Immunotherapy Response
January 26th 2023

"Persistent" Subset of Tumor Mutations May Predict Immunotherapy Response

Rose McNulty
A study published in Nature Medicine found that certain tumor mutations are more persistent and may predict immunotherapy responses more reliably than overall tumor mutational burden.
Lymphoma cell
January 19th 2023

Axi-cel Shows Improved Quality-Adjusted Survival Versus Standard of Care in LBCL

Rose McNulty
A Q-TWiST analysis of ZUMA-7 trial data suggests that axicabtagene ciloleucel (axi-cel) in the second line is beneficial to quality-adjusted survival and is a viable option for patients with relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy.
Dr Alonso V. Pacheco
January 17th 2023

There Is a Need to Identify Patients Most Likely to Benefit From Immunotherapies, Says Dr Alonso V. Pacheco

Laura Joszt, MA Justina Petrullo
New immunotherapies are changing the shape of oncology care, but there is also a need for a system that provides these high-quality therapies to the patients most likely to benefit from them. This might mean doing an assessment and a deeper dive into patient functional status, says Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.
image of science
January 14th 2023

From Lymphomas to Myeloma, Bispecific Antibodies Make a Big Splash at ASH

Mary Caffrey
At the 2022 annual meeting of the American Society of Hematology (ASH), customized cancer immunotherapy treatments now share the limelight with bispecific antibodies, which made news across disease states from large B-cell lymphoma to follicular lymphoma to multiple myeloma; as their name suggests, these treatments aim at 2 targets, increasing their potency against cancer.
Image of a brain
January 10th 2023

Immune Profiling Study Offers Potential New Patient-Stratification Tools in Glioblastoma

Jared Kaltwasser
The findings include the identification of a 12-gene signature that could be used to categorize patients as high or low risk.
image of chimeric antigen receptor (CAR) T-cell
January 7th 2023

How CAR T Therapies Stack Up Against Standard of Care for LBCL Across Lines of Treatment, Cost Perspectives

Christina Mattina
During 2022, the FDA approved 2 chimeric antigen receptor (CAR) T-cell therapies for use in second-line treatment, offering new treatment choices but raising the question: What options remain once a patient relapses after CAR T?
research shows Disparate CAR T-Cell Therapy Access and Outcomes in MM, DLBCL
January 7th 2023

ASH Abstracts Reveal Disparate CAR T-Cell Therapy Access and Outcomes in MM, DLBCL

Christina Mattina
Access to and outcomes of chimeric antigen receptor (CAR) T-cell therapies may differ by characteristics such as race, ethnicity, gender, and geographic location among patients with cancer.
the top 5 IVBM coverage of 2022
December 27th 2022

Top Institute for Value-Based Medicine® Content in 2022

Hayden E. Klein
Across several Institute for Value-Based Medicine® (IVBM) events held in 2022, the most-viewed content from these events cover a variety of topics in oncology care.
Graphic with wording "top 5 Evidence-Based Oncology articles of 2022"
December 24th 2022

Top Articles From Evidence-Based Oncology™ in 2022

In 2022, the most-read articles published in Evidence-Based Oncology™ included the latest updates in cancer treatments, the promises and challenges of technology, and a look at the shifting landscape of care delivery.
Top 5 Most-Read Immuno-Oncology Articles of 2022
December 22nd 2022

Top 5 Most-Read Immuno-Oncology Articles of 2022

AJMC Staff
In 2022, the most-read news about immuno-oncology included an FDA approval for liver cancer, research findings on other potential therapies for liver cancer, a Q&A with a COTA Healthcare executive about how real-world evidence has changed, new possibilities for patients with solid tumors, and more.
EBO logo
December 21st 2022

Data Sharing From Cancer Drug Trials Falls Short of Promises, Study Authors Say

Mary Caffrey
image of a health care provider and various icons indicating health and cost
December 13th 2022

ICYMI: Top Content From AMCP Annual Meeting

AJMC Staff
Among the conference highlights from the annual meeting of the Academy of Managed Care Pharmacy (AMCP) were an interview on chimeric antigen receptor T-cell therapies and a session on best practices for value-based contracting.
Image of a young male patient
December 8th 2022

Using Risk Factors to Guide CAR T Approach Before, After Infusion in B-ALL

Jaime Rosenberg
This paper follows the 10-year remission mark for the first child treated with CD19-targeted CAR (chimeric antigen receptor) T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL), adding promise to the notion that the technology can provide long-term durable remissions in patients who are highly refractory to chemotherapy.
ICYMI: Top Highlights From the 2022 Patient-Centered Oncology Care® Meeting
December 5th 2022

ICYMI: Top Highlights From the 2022 Patient-Centered Oncology Care® Meeting

AJMC Staff
axi-cel
December 3rd 2022

What Predicts Good Outcomes With Axi-cel? Investigators Support “Timely” Treatment

Mary Caffrey
Investigators from Fred Hutchison Cancer Research Center hoped to gain insights into what factors can predict success with axi-cel in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Abstract image of CAR T
November 23rd 2022

Drops in Serum Phosphate Levels May Help Predict Severe CRS After CAR T

Jaime Rosenberg
A new study has found that a drop in serum inorganic phosphate (iP) was an early predictor of severe cytokine release syndrome (CRS), suggesting that monitoring serum iP levels could help promote safer management of the most common toxicity associated with chimeric antigen receptor (CAR) T-cell therapy.
Stephen M. Schleicher, MD, MBA, Tennessee Oncology
November 14th 2022

Dr Stephen Schleicher: We Need to Focus More on Financial Toxicity

Maggie L. Shaw Mary Caffrey
Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, addresses the “huge problem” of financial toxicity among patients with cancer, which can be attributed in part to both the high price of targeted treatments and even from ordering only necessary testing.
graphic depicting research
November 8th 2022

Researchers Provide Management Recommendations for CRS, Other Toxicities of CAR T

Jaime Rosenberg
While chimeric antigen receptor (CAR) T-cell therapy has offered a new option and improved outcomes for patients with advanced hematologic malignancies, the treatment approach has been associated with toxicities such as cytokine release syndrome (CRS), neurotoxicity, and hematotoxicity.
CAR T
October 25th 2022

Are NK-Cell–Based Treatments the Next Approach in Immuno-Oncology?

Jaime Rosenberg
Highlighting their ability to quickly destroy malignant cells without antigen specificity, natural killer (NK) cells have been identified as an opportunity for use, particularly in cases where T cells are not effective.
Combination of Tremelimumab and Durvalumab Approved by FDA for Unresectable Liver Cancer
October 24th 2022

Combination of Tremelimumab and Durvalumab Approved by FDA for Unresectable Liver Cancer

AJMC Staff
A dual immunotherapy option of tremelimumab, sold as Imjudo, in combination with durvalumab, sold as Imfinzi, was approved by the FDA Monday for the treatment of adult patients with unresectable hepatocellular carcinoma, the most common type of liver cancer.
Image of biotechnology innovation
October 22nd 2022

Identifying ASCT-Ineligible Patients Who Could Benefit From CAR T-Cell Treatment

Jaime Rosenberg
Data suggest that the technology may be an option for patients who are ineligible for autologous stem cell transplantation (ASCT) based on certain patient characteristics, prior treatments, stem cell availability, or tumor chemosensitivity.
At Last, Artificial Intelligence Is Transforming Cancer Drug Discovery and Development
October 20th 2022

At Last, Artificial Intelligence Is Transforming Cancer Drug Discovery and Development

Dietmar Berger, MD, PhD
Review Underscores Potential and Obstacles of Universal CAR T-Cell Therapy
October 15th 2022

Review Underscores Potential and Obstacles of Universal CAR T-Cell Therapy

Rose McNulty
Despite the obstacles and risks, the review authors conclude that universal chimeric antigen receptor (CAR) T-cell therapy has the potential to play a key role and mitigate some of the limitations associated with autologous CAR T-cell therapy in cancer treatment.
CAR T
October 14th 2022

Advances and Limitations in CD20-Targeted CAR T-Cell Therapy

Rose McNulty
The review concludes that CD20-targeted chimeric antigen receptor (CAR) T-cell therapy is an option worth exploring, despite potential safety concerns that warrant more extensive research.
Kidneys
September 30th 2022

CAR T-Cell Therapy Outcomes Are Not Impacted by Baseline Renal Function, Study Finds

Rose McNulty
Renal outcomes and chimeric antigen receptor (CAR) T-cell therapy efficacy were unaffected by baseline renal status in a cohort of patients with diffuse large B cell lymphoma, but acute kidney injury during treatment was associated with worse clinical outcomes.
Image of cancer cells
September 17th 2022

Myeloid Cells Hold Promise as Cancer Immunotherapy Targets, Review Says

Rose McNulty
The review highlights current strategies for myeloid cell targeting and novel agents targeting myeloid cells for cancer treatment.
Image of immuno-oncology
September 7th 2022

Neurofilament Light Chain Levels May Indicate Risk of CAR T–Related Neurotoxicity

Rose McNulty
A significant portion of patients who receive chimeric antigen receptor (CAR) T-cell therapy experience immune effector cell–associated neurotoxicity syndrome, and this recent study suggests neurofilament light chain protein levels may hold promise as a biomarker to identify at-risk patients.
<12345678
...
15>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo